Marshall Wace North America L.P. Takes $179,000 Position in Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)

Marshall Wace North America L.P. bought a new stake in shares of Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 22,294 shares of the biotechnology company’s stock, valued at approximately $179,000. Marshall Wace North America L.P. owned approximately 0.08% of Aeglea Bio Therapeutics at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in AGLE. BNP Paribas Arbitrage SA acquired a new position in shares of Aeglea Bio Therapeutics in the 1st quarter worth $32,000. Canada Pension Plan Investment Board purchased a new position in shares of Aeglea Bio Therapeutics during the fourth quarter valued at $37,000. Meeder Asset Management Inc. grew its stake in Aeglea Bio Therapeutics by 38.4% in the first quarter. Meeder Asset Management Inc. now owns 7,083 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,967 shares in the last quarter. Bank of America Corp DE grew its stake in Aeglea Bio Therapeutics by 299.9% in the fourth quarter. Bank of America Corp DE now owns 17,145 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 12,858 shares in the last quarter. Finally, Millennium Management LLC purchased a new position in Aeglea Bio Therapeutics in the fourth quarter valued at about $156,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO Anthony G. Quinn bought 6,218 shares of the stock in a transaction on Friday, May 17th. The stock was purchased at an average price of $6.65 per share, for a total transaction of $41,349.70. Following the acquisition, the chief executive officer now owns 277,152 shares in the company, valued at $1,843,060.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Anthony G. Quinn acquired 12,217 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The stock was bought at an average price of $6.11 per share, with a total value of $74,645.87. Following the acquisition, the chief executive officer now directly owns 333,955 shares in the company, valued at $2,040,465.05. The disclosure for this purchase can be found here. Insiders have purchased a total of 92,177 shares of company stock worth $593,817 in the last ninety days. 12.60% of the stock is currently owned by company insiders.

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Aeglea Bio Therapeutics in a research note on Monday, June 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $14.33.

Shares of NASDAQ AGLE traded down $0.01 during trading hours on Friday, hitting $7.00. 102,877 shares of the company’s stock were exchanged, compared to its average volume of 211,361. The firm has a 50-day moving average of $6.51. The stock has a market cap of $202.23 million, a PE ratio of -3.29 and a beta of 1.00. Aeglea Bio Therapeutics Inc has a 1-year low of $5.99 and a 1-year high of $11.16.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, research analysts forecast that Aeglea Bio Therapeutics Inc will post -2.14 EPS for the current year.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

See Also: Cash Asset Ratio

Institutional Ownership by Quarter for Aeglea Bio Therapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.